Compare Incyte Corporation (INCY) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Manulife Financial Corporation — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while Manulife Financial Corporation trades at $43.58 (market cap $69.48B). The key difference: Manulife Financial Corporation is far larger — about 3× Incyte Corporation's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Manulife Financial Corporation for 119 Days on average.
| INCY | MFC | |
|---|---|---|
Market Cap | $22.85B | $69.48B |
Volume | 1,927,029 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $129.93 | $44.77 |
52-Week Low | $83.80 | $31.64 |
Typical Hold Time | 33 Days | 119 Days |
Enterprise Value | $18.35B | $64.75B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Manulife Financial (MFC) trades at $41.67, down 2.94% on the day, with a bearish technical signal from moving averages and oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B and a P/E of 16.22. Recent news includes a new $750M subordinated notes offering and executive appointments, while institutional investors like Bank of America added positions in Q2 2026.
The outlook is mixed: analyst consensus is Buy with a $34.24 target, but technicals suggest near-term pressure. Upside drivers include strong insurance sales and Asia growth, while risks involve premium valuation and macroeconomic sensitivity. Cash flow trends show improved operations, but net cash flow declined in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
